Veloxis Pharmaceuticals A/S Release: Phase 3 Clinical Study Data Demonstrating LCP-Tacro™’s Comparable Efficacy and Safety to Twice-Daily Tacrolimus Presented at the European Society for Organ Transplantation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in Vienna. Veloxis’ once-daily LCP-Tacro™, now with the trade name of Envarsus®, demonstrated comparable efficacy and safety compared to twice-daily tacrolimus (Prograf®).

Help employers find you! Check out all the jobs and post your resume.

Back to news